Imagine a tiny, life-saving device that dissolves harmlessly inside a child's body, potentially transforming their life after a liver transplant. That's the promise of biodegradable stents, a groundbreaking approach to treating a common complication in pediatric liver transplant patients. But here's where it gets controversial: while this procedure shows immense promise, its long-term effects and optimal use are still being debated. Could this be the future of pediatric transplant care, or are we moving too fast? Let’s dive in.
Recent research presented at the RSNA meeting on December 2nd sheds light on the safety and effectiveness of biodegradable stents in addressing bile duct narrowing—a challenging issue for young liver transplant recipients. Led by interventional radiologist Dr. Paolo Marra from Papa Giovanni XXIII Hospital in Bergamo, the 10-year study involved 102 pediatric patients across five Italian hospitals, with a median age of five years. The findings? Biodegradable stents not only appear safe but could also enhance the quality of life for these children, particularly those resistant to traditional treatments or suffering from recurring strictures.
Bile duct narrowing, or biliary strictures, often occurs due to scarring after liver transplants. In adults, biodegradable stents are already a go-to solution for benign cases. These stents widen the narrowed ducts, allowing them to heal and remodel naturally. But their use in children has been less explored—until now. Dr. Marra’s team aimed to fill this knowledge gap by evaluating the procedure’s outcomes in pediatric patients.
Here’s the breakdown: Of the 102 patients, 52 were boys and 50 were girls. Most had undergone liver transplants around the age of one and later developed strictures. At a median age of five, all received self-expandable polydioxanone-based stents. The researchers analyzed stricture characteristics, treatment timing, and the recurrence of strictures or complications.
At the start, 57% of patients had strictures longer than 10 mm, and 52% had involvement of the intrahepatic ducts. Stenting was performed approximately 55 days after the patients’ last biliary drainage. The results were impressive: 99% of cases were technically successful, with only 19% experiencing minor complications. Over a median follow-up of 793 days, 24% of patients saw strictures return, with a median recurrence time of 2,915 days.
Dr. Marra emphasized, “Biodegradable stents appear safe and effective for treating biliary strictures after pediatric liver transplantation.” But this is the part most people miss: while current standard treatments like balloon bilioplasty or external drainage are effective, they come with significant drawbacks. Drainage, for instance, requires children to carry external devices for months, drastically affecting their daily lives. Biodegradable stents, on the other hand, offer a less invasive, potentially more comfortable alternative.
However, the debate isn’t settled. Future research will explore why some stents fail and identify the best candidates and timing for this procedure. As Dr. Marra concluded, “Biodegradable biliary stents may revolutionize the management of biliary strictures in pediatric liver transplant patients, offering better outcomes with minimal invasiveness.”
But what do you think? Are biodegradable stents the future of pediatric transplant care, or should we proceed with caution? Share your thoughts in the comments below. And for more groundbreaking updates from RSNA 2025, don’t forget to check out our RADCast at https://www.auntminnie.com/resources/conference/rsna/2025.
